Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|Leptomeningeal Disease
Interventions: DRUG: High-dose Methotrexate (8 gm/m2; HD-MTX)
Sponsor: Wake Forest University Health Sciences
Collaborators: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins